BEIJING – Suzhou-based Innovent Biologics Inc. has inked a deal with Alector Inc. to obtain the rights of the U.S. biotech’s AL-008 to develop and commercialize it for oncology indications in China.
BEIJING – Suzhou-based Innovent Biologics Inc. has inked a deal with Alector Inc. to obtain the rights of the U.S. biotech’s AL-008, a dual function anti-SIRP-alpha (anti-signal regulatory protein-alpha) antibody, to develop and commercialize it for oncology indications in China.
BEIJING – The COVID-19 pandemic has temporarily impacted partnerships and investment opportunities, but it has also prompted other forms of collaboration within the biotech community.
BEIJING – China was the first country to face serious disruptions in clinical trials caused by COVID-19, and policy advocates in the country moved quickly to identify lessons for future outbreaks.
BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, made a strong debut to raise $288 million on the Hong Kong Stock Exchange (HKEX) on March 23, marking the second biggest IPO in the city since the beginning of this year.
BEIJING – Shanghai Junshi Biosciences Ltd. is developing neutralizing antibodies as a potential treatment for COVID-19, and the program will move on to clinical trials soon. Meanwhile, the biotech is set to launch a pre-revenue IPO on Shanghai’s STAR market.
BEIJING – Cell therapies specialist Nanjing Iaso Biotherapeutics Co. Ltd. pocketed $60 million in a series funding B round to advance its CT-103A, an anti-BCMA CAR T therapy candidate for multiple myeloma, among other plans.
BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, made a strong debut to raise $288 million on the Hong Kong Stock Exchange (HKEX) on March 23, marking the second biggest IPO in the city since the beginning of this year.
BEIJING – The COVID-19 pandemic has temporarily impacted partnerships and investment opportunities, but it has also prompted other forms of collaboration within the biotech community and helped R&D-driven companies learn valuable lessons.
BEIJING – China was the first country to face serious disruptions in clinical trials caused by COVID-19, and policy advocates in the country moved quickly to identify lessons for future outbreaks and address the concerns of a biotech industry in dismay.
